Biologics in patients with immune-mediated inflammatory diseases and malignancies: a study derived from two registries

Clicks: 5
ID: 325278
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #49 of 172 articles by views in clinical and experimental dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 172 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
We report our experience of biologic treatment in patients with immune-mediated inflammatory diseases and a recent personal history of cancer. Two registries were interrogated: (i) the MISTIC registry, which includes patients with a chronic inflammatory dermatological, rheumatic and/or gastroenterological disease who had started biologics since 2007, and (ii) the local tumour registry of the Doubs district. In total, 94 patients were included in 2 cohorts: 28 patients with cancer diagnosed within 5 years before starting biologics (cohort 1) and 66 patients who developed cancer during biologic treatment (cohort 2).
Reference Key
openalex_W7203698520 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Aymeric Hennemann, J. Castagna, Béranger Martin, Charline Vauchy, Anne Sophie Woronoff, Eric Toussirot, Lucine Vuitton, Clément Prati, F. Aubin
Journal clinical and experimental dermatology
Year 2026
DOI
10.1093/ced/llag191
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.